MedTrace Logo

A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa

NCT07756346 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-10

No results posted yet for this study

Summary

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease hidradenitis suppurativa (HS). In this study, the investigators will extend data from a 12-week pilot study to rigorously test the hypothesis that botulinum toxin (BoNT) therapy reduces disease severity and relieves HS pain symptoms..

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

DRUG

Botulinum Toxin A (Allergan, Inc, Irvine CA)

50U per axilla in 10 injections of 0.1mL

DRUG

Placebo

10 injections of 0.1mL of normal saline vehicle per laterality

Sponsors & Collaborators

  • Emory University

    collaborator OTHER

  • University of Massachusetts, Worcester

    lead OTHER

Principal Investigators

  • Sarah K Whitley, MD, PhD · UMass Chan Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2028-09-30
Completion
2029-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07756346 on ClinicalTrials.gov